Latest News

Tuesday, March 03, 2015 | Management/Leadership, STAAR Surgical

Caren Mason Appointed President and CEO of Staar Surgical Company

Caren Mason has been named President and Chief Executive Officer os Staar Surgical Company effective immediately. Ms. Mason, who was elected to Staar's board of directors in June 2014,…

Read the full story

Tuesday, March 03, 2015 | Acquisitions/Mergers

Actavis Said to Begin Bond Offering to Back Allergan Deal

Actavis Plc started selling bonds in what may the biggest corporate debt deal in two years to finance its purchase of Botox-maker Allergan Inc. The drug company will issue the securities as soon as Tu…

Read the full story

Tuesday, March 03, 2015 | Glaucoma

Neuroregeneration Research Promising for Glaucoma

Techniques for regenerating neurons damaged by glaucoma, which have had good results in animals, have improved vision in humans in a small preliminary trial. "We've made a lot of progress,&qu…

Read the full story

Tuesday, March 03, 2015 | CE Mark Approval, Oraya Therapeutics

Oraya Therapeutics' AMD Radiotherapy Device Receives New Indication of Use for Choroidal Metastases

Oraya Therapeutics announced that the Oraya IRay Radiotherapy system has received a CE Mark extension for the treatment of choroidal metastases, a cancer in the eye, originating most commonly from pri…

Read the full story

Tuesday, March 03, 2015 | Medical Studies

Ranibizumab Reverses Vision Loss Caused by Diabetes

Ranibizumab, a prescription drug commonly used to treat age-related vision loss, also reverses vision loss caused by diabetes among Hispanic and non-Hispanic whites, according to a new study led by in…

Read the full story

Tuesday, March 03, 2015 | Management/Leadership

Michael Monteferrante Elected to Board of National Association for the Employment of People who are Blind

Michael Monteferrante, President and CEO of Envision, has been elected to the board of directors of the National Association for the Employment of People Who Are Blind (NAEPB). Monteferrante was also …

Read the full story

Monday, March 02, 2015 | Santen

EMA Accepts Santan's Marketing Application Filing for Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis of the Posterior Segment

Santen Pharmaceutical announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorization application (MAA) filing for the use of intravitreal sirolimus, an inv…

Read the full story

Monday, March 02, 2015 | Clearside Biomedical

Clearside Biomedical Initiates Phase 2 Clinical Trial for Macular Edema Associated with Retinal Vein Occlusion Drug Candidate

Clearside Biomedical announced the enrollment of the first patient in a phase 2, randomized, controlled, masked, multicenter clinical trial for the treatment of macular edema associated with retinal v…

Read the full story

Monday, March 02, 2015 | Clinical Trials, Ohr Pharmaceutical

Ohr Pharmaceutical Announces Additional Positive Anatomic Data From the OHR-102 IMPACT Study Interim Analysis Presented at Annual Macula Society Meeting

Ohr Pharmaceutical announced the presentation of new data from the IMPACT study interim analysis at the 38th Annual Macula Society Meeting, which took place February 25-28, in Scottsdale, Arizona. The…

Read the full story

Monday, March 02, 2015 | Management/Leadership

Eyegate Pharmaceuticals Names Michael B. Raizman, MD, Consulting Chief Medical Officer

Eyegate Pharmaceuticals announced the appointment of Michael B. Raizman, MD, as the Consulting Chief Medical Officer. Dr. Raizman began working with the company as a consultant in the fourth quarter o…

Read the full story

Monday, March 02, 2015 | Shire

Shire Submits Application to the FDA for Approval of Lifitegrast For Treatment of Dry Eye Disease in Adults

Shire announced that the company has submitted a new drug application with the FDA for its investigational compound lifitegrast for the treatment of signs and symptoms of dry eye disease in adul…

Read the full story

Monday, March 02, 2015 | Clinical Trials

Implandata: First Keratoprosthesis Patient in Europe Receives Permanent Intraocular Pressure Sensor EyeMate

Implandata Ophthalmic Products announced the successful implantation of Implandata’s EyeMate intraocular pressure sensor on a first patient in Europe undergoing keratoprosthesis surgery, accordi…

Read the full story

Friday, February 27, 2015 | Clinical Trials, Alcon

Phase 2 Data Highlights Benefits of Alcon's RTH258 for Patients with Wet AMD

Alcon presented results from its second phase 2 clinical study of RTH258 during the 38th Annual Macula Society Meeting in Scottsdale, Arizona. The study evaluated the efficacy and safety of the compou…

Read the full story

Friday, February 27, 2015 | Acquisitions/Mergers, Optos

Nikon to Acquire Optos for $400 Million in Cash

Nikon Corp. has agreed to acquire retinal imaging firm Optos for $400 million (259.3 million pounds) in cash, the companies announced Friday. Under terms of the agreement, Nikon will pay 340 pence a s…

Read the full story

Friday, February 27, 2015 | Earnings & Financials

Ocata Therapeutics Approved for Listing on NASDAQ

Ocata Therapeutics, a clinical stage biotechnology company developing regenerative ophthalmology therapeutics, announced that it has received notice that the NASDAQ Listing Qualifications Department h…

Read the full story
Load More
 Stock Price  Change 
 Aerie Pharmaceuticals, Inc. $28.60  -1.14% 
 Akorn, Inc. $49.33  -8.15% 
 Alimera Sciences, Inc. $5.18  -0.38% 
 Allergan, Inc. $234.86  -0.40% 
 Avalanche $34.69  -5.73% 
 Bayer $147.55  -0.34% 
 Can-Fite Biopharma $4.50  -3.23% 
 Carl Zeiss Meditec $24.02  -1.94% 
 Cooper Companies, Inc. $164.77  -0.58% 
 Escalon Medical Corp. $1.53  0.86% 
 Essilor International $116.50  0.00% 
 Imprimis Pharmaceuticals, Inc. $7.83  -0.51% 
 InSite Vision, Inc. $0.20  -4.39% 
 IRIDEX Corporation $10.45  0.19% 
 Johnson & Johnson $102.34  -0.85% 
 LCA-Vision Inc. $5.37  0.00% 
 Luxottica Group, S.p.A. $60.27  -5.75% 
 Merck & Company, Inc. $58.34  -0.41% 
 NicOx $2.15  -0.51% 
 NovaBay Pharmaceuticals, Inc. $0.59  -1.67% 
 Novartis AG Common Stock $99.06  -1.01% 
 Ocular Therapeutix $35.98  1.30% 
 Ophthotech Corporation $53.87  -0.15% 
 Quantel $3.29  -3.24% 
 Regeneron $412.51  -1.42% 
 Roche $34.35  1.07% 
 STAAR Surgical Company $7.76  13.78% 
 TearLab Corporation $2.60  -0.38% 
 Thrombogenics $8.50  0.00% 
 Topcon Corporation $19.85  0.00% 
 Valeant Pharmaceuticals $202.61  -0.36% 
 Xoma $3.73  -0.27%